Investment firms B Capital Group and Sanabil led a $123 Series B round in Atomwise, a drug discoverer and manufacturer. The funding round includes returning investors Data Collective, Baidu Ventures, Tencent, Y Combinator, Dolby Family Ventures, and AME Cloud Ventures. “Over the past three years, our platform AtomNet® has tackled — and succeeded - in finding small molecule hits for more undruggable targets than any other AI drug discovery platform. With support from our new and existing investment partners, we will be able to leverage this to develop our own pipeline of small molecule drug programs, further grow our portfolio of joint-venture investments, and realize our vision to create better medicines that can improve the lives of billions of people," Abraham Heifets, Atomwise CEO and Co-Founder.